Pharmacokinetics of Ulonivirine in Mild or Moderate Hepatic Impairment

Phase 1, open-label trial of ulonivirine in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Dosing to Infinity at 504 hours, Area Under the Plasma Concentration-Time Curve from Dosing to Last Measurable Concentration at 504 hours and 5 more. Planned start Jan 2027; status: not yet recruiting.